Please login to the form below

Not currently logged in
Email:
Password:

Blueprint Medicines

This page shows the latest Blueprint Medicines news and features for those working in and with pharma, biotech and healthcare.

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

FDA) and the European Medicines Agency (EMA). ... The positive readout comes just a few weeks after Roche’s Genentech unit and Blueprint Medicines received full approval from the FDA for use of their targeted cancer therapy, Gavreto (pralsetinib),

Latest news

More from news
Approximately 7 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    And Blueprint Medicines created a proprietary PRO for its mastocytosis drug. ... Blueprint Medicines is one company that took matters into its own hands.

  • Spotlight on Patient Engagement Spotlight on Patient Engagement

    Open Conversations: Pathway to Launch Excellence It is widely acknowledged that yesterday’s playbook no longer provides the best blueprint for launching tomorrow’s medicines.

  • Open Conversations: Pathway to Launch Excellence Open Conversations: Pathway to Launch Excellence

    Open Conversations: Pathway to Launch Excellence. It is widely acknowledged that yesterday’s playbook no longer provides the best blueprint for launching tomorrow’s medicines.

  • Deal Watch March 2016 Deal Watch March 2016

    Roche has paid $45m upfront with $965m in contingent fees, including options, milestones and royalties for the rights to up to five small molecules from Blueprint Medicines' drug discovery platform. ... Acquisition of royalty rights. $1, 140. Blueprint

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
11 London

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...